Skip to main content

An Important Advance in the Treatment of Advanced Gastrointestinal Stromal Tumor (GIST)

April 16, 2021

Brought to you by Deciphera Pharmaceuticals

Deciphera Pharmaceuticals invites you to join an expert-led discussion: Advancements in the Clinical Management of Advanced Gastrointestinal Stromal Tumor during our Product Theater at the 2021 ONS Annual Congress on April 29, 2021 at 2:00 PM EST. Sandra Brackert, NP-C, will review the first and only switch-control kinase inhibitor for advanced GIST and it’s impact on the clinical management of your GIST patients. GIST is the most common sarcoma of the GI tract and is often driven by primary activating mutations in tyrosine kinase genes, KIT, and PDGFRA. The diagnosis and treatment of GIST has evolved over the past decades, and until recently, there were no approved therapies for 4L GIST. 

Register today for this educational program offered in partnership with the 2021 ONS Congress: 

Click here to register for the program! 

Blog category